UMass Chan clinical trial reveals antisense oligonucleotide safely suppresses mutant ALS gene in pilot human study

WORCESTER, Mass. – Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan

Related Keywords

United States ,United Kingdom ,Morningside ,North Lanarkshire ,Helene Tran ,Theresam Lachance ,Umass Chan ,Jonathan Watts ,Roberth Brown Jr ,Craigc Mello ,Th Chan School Of Medicine ,Blais University ,Oxford University Medical School ,University Of Massachusetts ,Morningside Graduate School Of Biomedical Sciences ,Cellucci Fund ,Umass Chan Medical School ,Tan Chingfen Graduate School Of Nursing ,National Institutes Of Health ,Drug Administration ,Howard Hughes Medical Institute Investigator ,Therapeutics Institute ,Watts Lab ,Angel Fund ,Morningside Foundation ,Stanford University ,Research Fund ,Chan Medical School ,Nature Medicine ,Chance Chair ,Medical Research ,Michael Moazami Phd ,National Institutes ,Max Rosenfeld ,Morningside Graduate School ,Biomedical Sciences ,Tan Chingfen Graduate School ,Medical School ,Chan Medical ,Blais University Chair ,Molecular Medicine ,Nobel Prize ,